Next-generation dengue vaccines: Novel strategies currently under development

Anna P. Durbin, Stephen S. Whitehead

Research output: Contribution to journalArticlepeer-review


Dengue has become the most important arboviral infection worldwide with more than 30 million cases of dengue fever estimated to occur each year. The need for a dengue vaccine is great and several live attenuated dengue candidate vaccines are proceeding through clinical evaluation. The need to induce a balanced immune response against all four DENV serotypes with a single vaccine has been a challenge for dengue vaccine developers. A live attenuated DENV chimeric vaccine produced by Sanofi Pasteur has recently entered Phase III evaluation in numerous dengue-endemic regions of the world. Viral interference between serotypes contained in live vaccines has required up to three doses of the vaccine be given over a 12-month period of time. For this reason, novel DENV candidate vaccines are being developed with the goal of achieving a protective immune response with an immunization schedule that can be given over the course of a few months. These next-generation candidates include DNA vaccines, recombinant adenovirus vectored vaccines, alphavirus replicons, and sub-unit protein vaccines. Several of these novel candidates will be discussed.

Original languageEnglish (US)
Pages (from-to)1800-1814
Number of pages15
Issue number10
StatePublished - Oct 2011


  • DNA vaccine
  • Dengue vaccine
  • Sub-unit protein vaccine
  • Vectored-vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology


Dive into the research topics of 'Next-generation dengue vaccines: Novel strategies currently under development'. Together they form a unique fingerprint.

Cite this